MediWound

163 articles with MediWound

• MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update

  3/16/2023

  MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced financial results for the fourth quarter and the year ended December 31, 2022 and provided a corporate update.

• MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer

  3/16/2023

  MediWound Ltd. is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023.

• MediWound Expands its Global Leadership Team to Help Drive Company’s Future Growth

  3/6/2023

  MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced the appointment of Barry Wolfenson as Executive Vice President of Strategy & Corporate Development.

• MediWound to Report Fourth Quarter and Year-End 2022 Financial Results Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time

  3/2/2023

  MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2022 on Thursday, March 16, 2023.

• MediWound to Present Corporate Highlights at Upcoming March 2023 Investor Conferences

  2/23/2023

  MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced management will present at two upcoming investor conferences in March.

• MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares

  2/7/2023

  MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced the closing of its previously announced registered direct offering.

• MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market

  2/3/2023

  MediWound Ltd. announced that it has entered into a definitive securities purchase agreement for the sale and purchase of1,964,286 shares of the Company’s ordinary shares, par value NIS 0.07, at a purchase price of $14 per share, in a registered direct offering.

• MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

  12/29/2022

  MediWound Ltd. announced that the U.S. Food and Drug Administration has approved NexoBrid® for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns.

• MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan

  12/23/2022

  MediWound Ltd. today announced that its partner, Kaken Pharmaceutical Co., Ltd. has gained marketing approval of NexoBrid® in Japan.

• MediWound Strengthens European Presence of NexoBrid®

  12/20/2022

  MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the marketing approval of NexoBrid® in Switzerland.

• MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

  12/19/2022

  MediWound Ltd. today announced positive data from its Phase I/II study to evaluate the safety and efficacy of MW005 in the treatment of low-risk Basal Cell Carcinoma (BCC).

• MediWound Expands Global Presence as NexoBrid® Gains Approval in India

  12/13/2022

  MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced it has gained marketing approval of NexoBrid® in India.

• MediWound Announces a 1-for-7 Reverse Share Split

  12/5/2022

  MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced that it intends to effect a 1-for-7 reverse share split of its ordinary shares.

• MediWound Reports Third Quarter 2022 Financial Results and Provides Company Update

  11/15/2022

  MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced financial results for the third quarter ended September 30, 2022 and provided a corporate update.

• MediWound’s EscharEx Featured in Paper as a Potential Paradigm Shift Towards Non-Surgical Wound Bed Preparation in DFUs

  11/9/2022

  MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced the publication of a paper, “Introducing Bromelain-Based Enzymatic Debridement” in the journal Podiatry Management.

• MediWound to Report Third Quarter 2022 Financial Results

  11/3/2022

  MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced that the Company will release its financial results for the third quarter ended September 30, 2022 on Tuesday, November 15, 2022.

• MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022

  10/18/2022

  MediWound Ltd. today announced that positive clinical data from the Company’s EscharEx ® Phase 2 trials was featured in an oral and two poster presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022 Conference in Las Vegas, Nevada.

• MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings

  10/7/2022

  MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced the closing of its previously announced registered direct and PIPE offerings.

• EMA Accepts MediWound’s Application for Extended Indication for NexoBrid to Treat Pediatric Patients with Severe Thermal Burns

  9/20/2022

  MediWound Ltd. today announced that the European Medicines Agency (EMA) has validated for review the Type II Variation submitted by MediWound in order to expand the current approved indication for NexoBrid (removal of eschar in adults with deep partial-and full-thickness thermal burns.

• MediWound’s NexoBrid® Highlighted in 45 Posters and Presentations at the 19th European Burns Association Congress

  9/12/2022

  MediWound Ltd. announced its successful and meaningful presence at the recently concluded 19th European Burns Association Congress held in Turin, Italy on September 7-10, 2022.